Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Notable treatments include Tezspire, for severe asthma, and Saphnelo, for lupus-related conditions. The company’s future strategy centers on disease modification, expanding treatment options and ...

Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...

A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...

The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...

T HURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

A newer lupus drug can protect patients from long-term organ damage Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in ...